Impax Drug Patent Portfolio

Impax owns 5 orange book drugs protected by 25 US patents with Twinject 0.15 having the least patent protection, holding only 2 patents. And Crexont with maximum patent protection, holding 10 patents. Given below is the list of Impax's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11986449 Levodopa dosing regimen 21 Dec, 2041
Active
US10098845 Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof 07 Oct, 2034
Active
US10292935 Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof 07 Oct, 2034
Active
US10688058 Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof 07 Oct, 2034
Active
US10973769 Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof 07 Oct, 2034
Active
US10987313 Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof 07 Oct, 2034
Active
US11357733 Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof 07 Oct, 2034
Active
US11622941 Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof 07 Oct, 2034
Active
US11666538 Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof 07 Oct, 2034
Active
US12064521 Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof 07 Oct, 2034
Active
US8377474 Controlled release formulations of levodopa and uses thereof 26 Dec, 2028
Active
US8454998 Controlled release formulations of levodopa and uses thereof 26 Dec, 2028
Active
US8557283 Controlled release formulations of levodopa and uses thereof 26 Dec, 2028
Active
US9089607 Controlled release formulations of levodopa and uses thereof 26 Dec, 2028
Active
US9089608 Controlled release formulations of levodopa and uses thereof 26 Dec, 2028
Active
US9463246 Controlled release formulations of levodopa and uses thereof 26 Dec, 2028
Active
US9533046 Controlled release formulations of levodopa and uses thereof 26 Dec, 2028
Active
US9901640 Controlled release formulations of levodopa and uses thereof 26 Dec, 2028
Active
US7905352 Kits containing medicine injection devices and containers 12 Apr, 2027
Active
US7621891 Method and apparatus for delivering epinephrine 04 Feb, 2025
Active
US10166334 Medicine injection apparatuses 21 Jan, 2025
Active
US10166344 Injection needle assembly 21 Jan, 2025
Active
US7297136 Medicine injection devices and methods 18 Jan, 2025
Active
US7094427 Combination immediate release controlled release levodopa/carbidopa dosage forms 29 May, 2022 Expired
US5665071 Reloadable automatic or manual emergency injection system 27 May, 2013 Expired


Given below is the list of recent legal activities going on the following drug patents of Impax.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 03 Jul, 2024 US9533046
Payment of Maintenance Fee, 8th Year, Large Entity 11 Apr, 2024 US9463246 (Litigated)
Email Notification 24 May, 2023 US8377474 (Litigated)
Change in Power of Attorney (May Include Associate POA) 24 May, 2023 US8377474 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 30 Jan, 2023 US9089607 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 30 Jan, 2023 US9089608 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 10 Aug, 2022 US7905352
Payment of Maintenance Fee, 4th Year, Large Entity 21 Jun, 2022 US10166344
Payment of Maintenance Fee, 4th Year, Large Entity 31 May, 2022 US10166334
Payment of Maintenance Fee, 4th Year, Large Entity 11 Aug, 2021 US9901640
Payment of Maintenance Fee, 8th Year, Large Entity 31 Mar, 2021 US8557283 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 18 Dec, 2020 US7621891
Payment of Maintenance Fee, 12th Year, Large Entity 18 Dec, 2020 US7621891
Payment of Maintenance Fee, 8th Year, Large Entity 25 Sep, 2020 US8454998 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 06 Aug, 2020 US8377474 (Litigated)


Impax Drug Patents' Oppositions Filed in EPO

Impax drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 07, 2021, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP08866933A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP08866933A Jan, 2021 Luigi, Rumi Granted and Under Opposition
EP08866933A Jan, 2021 Teva Pharmaceutical Industries Ltd. Granted and Under Opposition


Impax's Family Patents

Impax drugs have patent protection in a total of 18 countries. It's US patent count contributes only to 37.8% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Impax Drug List

Given below is the complete list of Impax's drugs and the patents protecting them.


1. Adrenaclick

Adrenaclick is protected by 4 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7905352 Kits containing medicine injection devices and containers 12 Apr, 2027
(2 years from now)
Active
US10166334 Medicine injection apparatuses 21 Jan, 2025
(3 months from now)
Active
US10166344 Injection needle assembly 21 Jan, 2025
(3 months from now)
Active
US5665071 Reloadable automatic or manual emergency injection system 27 May, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Adrenaclick's drug page


2. Crexont

Crexont is protected by 10 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11986449 Levodopa dosing regimen 21 Dec, 2041
(17 years from now)
Active
US10098845 Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof 07 Oct, 2034
(9 years from now)
Active
US10292935 Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof 07 Oct, 2034
(9 years from now)
Active
US10688058 Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof 07 Oct, 2034
(9 years from now)
Active
US10973769 Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof 07 Oct, 2034
(9 years from now)
Active
US10987313 Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof 07 Oct, 2034
(9 years from now)
Active
US11357733 Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof 07 Oct, 2034
(9 years from now)
Active
US11622941 Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof 07 Oct, 2034
(9 years from now)
Active
US11666538 Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof 07 Oct, 2034
(9 years from now)
Active
US12064521 Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof 07 Oct, 2034
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Crexont's drug page


3. Rytary

Rytary is protected by 9 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8377474 Controlled release formulations of levodopa and uses thereof 26 Dec, 2028
(4 years from now)
Active
US8454998 Controlled release formulations of levodopa and uses thereof 26 Dec, 2028
(4 years from now)
Active
US8557283 Controlled release formulations of levodopa and uses thereof 26 Dec, 2028
(4 years from now)
Active
US9089607 Controlled release formulations of levodopa and uses thereof 26 Dec, 2028
(4 years from now)
Active
US9089608 Controlled release formulations of levodopa and uses thereof 26 Dec, 2028
(4 years from now)
Active
US9463246 Controlled release formulations of levodopa and uses thereof 26 Dec, 2028
(4 years from now)
Active
US9533046 Controlled release formulations of levodopa and uses thereof 26 Dec, 2028
(4 years from now)
Active
US9901640 Controlled release formulations of levodopa and uses thereof 26 Dec, 2028
(4 years from now)
Active
US7094427 Combination immediate release controlled release levodopa/carbidopa dosage forms 29 May, 2022
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rytary's drug page


4. Twinject 0.15

Twinject 0.15 is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7621891 Method and apparatus for delivering epinephrine 04 Feb, 2025
(3 months from now)
Active
US7297136 Medicine injection devices and methods 18 Jan, 2025
(3 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Twinject 0.15's drug page


5. Twinject 0.3

Twinject 0.3 is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7621891 Method and apparatus for delivering epinephrine 04 Feb, 2025
(3 months from now)
Active
US7297136 Medicine injection devices and methods 18 Jan, 2025
(3 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Twinject 0.3's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List